Amneal Pharmaceuticals Earnings Call: Growth Amid Transition

Amneal Pharma ((AMRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Amneal Pharmaceuticals’ latest earnings call painted a cautiously optimistic picture, with clear evidence of financial momentum tempered by acknowledged execution risks. Management emphasized solid revenue and profit growth, improving margins and leverage, and a pivot toward higher-value products, while warning that launch timing, price pressure, and segment-specific headwinds could limit near-term upside.

Revenue and Profitability Climb in 2025

Amneal reported full-year 2025 revenue of $3.0 billion, an 8% increase year over year, underscoring a steady growth trajectory despite a competitive generic backdrop. Adjusted EBITDA rose 10% to $688 million and adjusted EPS jumped 43% to $0.83, signaling expanding profitability and operating leverage as the portfolio shifts toward higher-margin assets.

Q4 Delivers Strong Finish to the Year

The company closed 2025 with a robust fourth quarter, posting revenue of $814 million, up 11% from a year earlier, driven by both core generics and specialty momentum. Adjusted EBITDA for Q4 grew 13% to $175 million and adjusted EPS surged 75% to $0.21, suggesting accelerating earnings power exiting the year.

Specialty Segment Emerges as Growth Engine

Specialty revenues climbed 19% for the full year and an impressive 38% in the fourth quarter to $167 million, reflecting strong uptake of branded therapies. Management highlighted contributions from Krexone and the new migraine auto-injector, underscoring the segment’s role in driving mix improvement and diversifying away from pure commodity generics.

Balance Sheet and Cash Flow Strengthen

Operating cash flow reached $340 million in 2025, providing the fuel for pipeline investment and debt reduction. Net leverage has fallen to 3.5x from 7.4x in 2019, while the weighted average cost of debt dropped from roughly 10% to about 6.8% by 2026 and interest expense declined to $217 million, with maturities now extended to 2032.

2026 Outlook: Modest Growth, Better Margins

For 2026, Amneal guided revenue to $3.05–3.15 billion, implying 1–4% growth, with adjusted EBITDA expected between $720 million and $760 million, up 5–10%. Adjusted EPS is forecast at $0.93–$1.03, a 12–20% increase, and adjusted gross margin is seen topping 44%, roughly 100 basis points higher as mix shifts toward complex and branded products.

Complex Pipeline and Launch Cadence Build Optionality

The company laid out an aggressive development agenda, planning to file 10–15 key complex programs in 2026 as it leans further into harder-to-make generics. With 59 ANDAs pending, 64% of them complex, and another 52 products in development, of which 94% are complex, Amneal is targeting 20–30 new Affordable Medicines launches annually to sustain growth.

Biosimilars and GLP‑1 Franchise Take Shape

Biosimilars remain a central pillar, with approvals for two additional products putting Amneal on pace for six U.S. biosimilars by 2027 and ZOLAR under review targeting the sizable Xolair market. The GLP‑1 collaboration with Pfizer is progressing, and the company said two GLP‑1 manufacturing facilities are on schedule, positioning Amneal for a foothold in a fast-growing therapeutic class.

New Specialty Brands Gain Commercial Traction

Krexone is seeing encouraging uptake one year after launch, with about 23,000 patients on therapy and early data suggesting meaningful improvements in “good on” time for patients switching from immediate-release regimens. Management believes it can roughly double Krexone’s market share and more than double its revenue in 2026, while the first-of-its-kind severe migraine and cluster headache auto-injector is experiencing stronger-than-expected early demand.

Affordable Medicines Face Near-Term Volatility

The Affordable Medicines segment delivered only modest growth, essentially flat in the fourth quarter at $437 million and up 4% for full-year 2025, as the timing of launches muted momentum. Management expects an acceleration in 2026–2027 as the complex pipeline comes through, but near-term performance will depend heavily on the successful rollout and ramp of new generic products.

AvKARE Reset to Pressure 2026 Revenue

AvKARE generated $745 million in revenue in 2025, up 12% year over year, but that contribution is expected to step down in 2026 to $625–$700 million. The decline reflects a deliberate move away from lower-margin distribution and the loss of a roughly $100 million generic product to intensified competition, trading top-line dollars for improved overall profitability.

Specialty Faces Generic Erosion Headwind

Despite the momentum of newer brands, management expects the specialty segment to be roughly flat in 2026 as growth from Krexone and others is offset by generic erosion of Rytary. This dynamic shows the inherent volatility in specialty portfolios where a single loss of exclusivity can dampen segment growth, even amid successful launches.

Pricing and Access Pressure on New Brands

Executives pointed to typical gross-to-net discounts of 40–45% for products such as Krexone, signaling heavy rebate and access costs to secure coverage. Early in the launch, as many as 35% of prescriptions could not be filled due to pricing and payer hurdles, underscoring that real-world access and discount pressure remain key constraints on branded revenue ramp.

Launch Timing and Supply Chain Constrain Near-Term Upside

Several complex product launches, including the iohexol generic to Omnipaque and select inhalation and injectable products, are expected to contribute meaningfully only from 2027 onward. Manufacturing and supply-chain complexity is pushing back the revenue curve, meaning that while the opportunity set is large, its impact on 2026 numbers will be more gradual than step-change.

Execution Risks Across Multiple Growth Vectors

Management acknowledged that its growth story rests on hitting many forward milestones, from biosimilar approvals and commercialization to GLP‑1 capacity build-out and the smooth launch of numerous complex generics. This multi-front strategy widens the opportunity but introduces execution and timing risk, leaving investors with a compelling pipeline but less near-term visibility.

Guidance Signals Steady Progress with Capped Upside

For 2026, the company expects operating cash flow of $325–$375 million, roughly in line with 2025, alongside capital spending of around $110 million, or about 3% of revenue, as it invests in capacity and complex capabilities. Management also anticipates continued balance-sheet improvement, with net leverage holding near 3.5x and interest expense easing further as lower-cost debt and extended maturities support financial flexibility.

Amneal’s earnings call portrayed a company steadily shifting toward differentiated, higher-margin products while shoring up its capital structure, which should support earnings growth even as top-line expansion moderates. Investors will need patience as biosimilars, GLP‑1 manufacturing, and complex generics ramp over several years, but if execution holds, the current transition could lay the groundwork for a more durable and profitable growth profile.